Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary report

Cancer Science

Volumn 103, Issue 5, 2012, Pages 921-925

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Osaki, Yukio ^b   Tada, Toshifumi ^a   Kaneoka, Yuji ^a   Maeda, Atsuyuki ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; LENS CULINARIS AGGLUTININ REACTIVE FRACTION OF ALPHA FETOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MU 3; MONOCLONAL ANTIBODY P 11; MONOCLONAL ANTIBODY P 16; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TEST; CANCER DIAGNOSIS; CANCER PATIENT; CHEMOLUMINESCENCE; CONTROLLED STUDY; DECARBOXYLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ELECTROIMMUNOASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WARFARIN;

EID: 84860249731     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02232.x     Document Type: Article

References (30)

1. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305: 242-8.
2. Bajaj SP, Price PA, Russell WA. Decarboxylation of gamma-caboxyglutamic acid residues in human prothrombin. J Biol Chem 1982; 257: 3726-31.
3. Kuromatsu R, Tanaka M, Shimauchi Y et al. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol 1997; 32: 507-12.
4. Liebman HA, Furie BC, Tong MJ et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
5. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988; 61: 1621-8.
6. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-8.
7. Deyashiki Y, Nishioka Y, Takahashi K, Kosaka Y, Suzuki K. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma. Cancer 1989; 64: 2546-51.
8. Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989; 49: 6493-7.
9. Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 1545-52.
10. Naraki T, Kohno N, Saito H et al. Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochem Biophys Acta 2002; 1586: 287-98.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
12. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, English edn. Tokyo: Kanehara, 2003.
13. Kagebayashi C, Yamaguchi I, Akinaga A et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009; 388: 306-11.
14. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
15. Koda M, Murawaki Y, Mitsuda A et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000; 88: 529-37.
16. Toyoda H, Kumada T, Tada T et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein < 20 ng/mL. Cancer Sci 2011; 102: 1025-31.
17. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2002; 55: 74-108.
18. Befeler AS, DiBisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
19. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37: S95-100.
20. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
21. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-23.
22. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
23. Taketa K, Sekiya C, Namiki N et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99: 508-18.
24. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62: S57-63.
25. Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
26. Toyoda H, Kumada T, Kaneoka Y et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49: 223-32.
27. Kobayashi M, Ikeda K, Kawamura Y et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-80.
28. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassay in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-4.
29. Toyoda H, Kumada T, Kiriyama S et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 111-7.
30. Toyoda H, Kumada T, Osaki Y et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006; 4: 1528-36.